Vimarsana
Biggest News Aggregation in the World

Page 12 - Oral Solution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oral Solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oral Solution Today - Breaking & Trending Today

Tata Motors to Increase Prices of Commercial Vehicles - Vimarsana News

Tata Motors to Increase Prices of Commercial Vehicles

Tata Motors to Increase Prices of Commercial Vehicles - Clayton County Register

InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets - Vimarsana News

InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets

Cipla Limited today announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level.

Source: fda.gov
Seal Integrity Issue Prompts Recall of Pouches Containing Seizure Medication Vigabatrin - Vimarsana News

Seal Integrity Issue Prompts Recall of Pouches Containing Seizure Medication Vigabatrin

Cipla’s subsidiary InvaGen Pharmaceuticals is recalling 1 lot of Vigabatrin for Oral Solution 500mg due to seal integrity issues that result in the powder leaking from the pouch.

Source: empr.com
Cipla's arm InvaGen Pharma USA recalls anti-epileptic drug due to packaging issues - Vimarsana News

Cipla's arm InvaGen Pharma USA recalls anti-epileptic drug due to packaging issues

The product is used for the treatment of refractory complex partial seizures as adjunctive therapy in patients 2 years of age and older

Cipla unit recalls anti-epileptic drug in US over pouch leakage issues - Vimarsana News

Cipla unit recalls anti-epileptic drug in US over pouch leakage issues

Cipla, in a regulatory filing, said InvaGen Pharmaceuticals is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP (500 mg), at the consumer level due to seal integrity issues, allowing for powder leakage from the pouch